Extracellular matrix as target for antitumor therapy

• Main Authors: Harisi R, Jeney A
• Format: Article
• Language: English
• Published: Dove Medical Press 2015-06-01
• Series: OncoTargets and Therapy
• Online Access: http://www.dovepress.com/extracellular-matrix-as-target-for-antitumor-therapy-peer-reviewed-article-OTT

Revekka Harisi, Andras Jeney 1st Institute of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, Budapest, Hungary Abstract: The aim of the present review is to survey the accumulated knowledge on the extracellular matrix (ECM) of tumors referring to its putative utility as therapeutic target. Following the traditional observation on the extensive morphological alteration in the tumor-affected tissue, the well-documented aberrant cellular regulation indicated that ECM components have an active role in tumor progression. However, due to the diverse functions and variable expression of proteoglycans, matrix proteins, and integrins, it is rather difficult to identify a comprehensive therapeutic target among ECM components. At present, the elevated level of heparanase and the prominent expression of αvβ5 integrin are considered as promising therapeutic targets. The inhibition of glycosaminoglycan offers another promising approach in the treatment of those tumors which are stimulated by proteoglycans. It can be ascertained that a selective ECM inhibitor would be a great asset to control metastasis driven by ECM-mediated signaling. Keywords: tumor microenvironment, tumor progression, three-dimensional ECM, heparan sulfate proteoglycan